The association between the effects of WEE1 inhibitors and p53 or KRAS mutation status has been investigated in various cancers; however, some studies have highlighted the correlation between p53 or KRAS mutation status and the effects of WEE1 inhibitors [7], whereas others have not [13]. This evidence concerns the gene TP53 and cancer.